| Business Summary | | Visible
Genetics
Inc.
develops,
manufactures
and
sells
integrated
DNA
sequencing
systems
that
analyze
genetic
information
to
improve
the
treatment
of
selected
diseases.
The
Company's
strategy
is
to
become
a
leader
in
the
emerging
field
of
pharmacogenomics,
the
science
of
individualizing
therapy
based
on
genetic
differences
across
patients.
Visible
Genetics'
genotyping
technology,
which
employs
DNA
sequencing,
enables
the
analysis,
in
the
clinical
diagnostic
laboratory,
of
individual
genetic
variations.
The
Company
believes
that
individualizing
therapy
through
pharmacogenomics
will
improve
the
treatment
of
many
diseases,
such
as
those
caused
by
Human
Immunodeficiency
Virus
(HIV),
hepatitis
B,
hepatitis
C,
tuberculosis
and
eventually
some
cancers. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Visible
Genetics
Inc.
develops,
manufactures
and
markets
automated
DNA
sequencing
systems
and
provides
genotyping
testing
services
for
HIV
and
other
diseases.
For
the
six
months
ended
6/30/01,
sales
increased
6%
to
$7.5
million.
Net
loss
applicable
to
Common
increased
28%
to
$19.6
million.
Revenues
reflect
increased
sequencing
systems
sales.
Higher
loss
reflects
higher
personnel-related
and
R&D
expenses,
and
$540
thousand
in
exit
and
termination
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Richard Daly, 51 Pres,
CEO | $351K | Thomas Clarke, 52 CFO | 159K | Timothy Ellis, 53 COO | 180K | Arthur Cole Dr., 50 Exec.
VP; Pres, Visible Genetics Europe S.A. | 208K | Marguerite Ethier, 37 VP,
Gen. Counsel, Director | 142K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|